Membrane and soluble <scp>T</scp>oll‐like receptor 2 in patients with psoriasis treated by <scp>G</scp>oeckerman therapy

Kondělková, Kateřina; Krejsek, Jan; Borská, Lenka; Fiala, Zdeněk; Hamáková, Květoslava; Andrýs, Ctirad

doi:10.1111/ijd.12381

Cited by 9 publications

(10 citation statements)

References 37 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…We showed that Goeckerman therapy induces immunomodulatory, immunosuppressive, and anti-inflammatory effects in our previous studies [ 10 , 12 , 34 ]. In accordance with these results and results of other authors we observed the decrease of proinflammatory CRP and leptin after the therapy which was significant in the case of CRP.…”

Section: Discussionmentioning

confidence: 99%

Selected Inflammatory and Metabolic Markers in Psoriatic Patients Treated with Goeckerman Therapy

Kondělková

Borská

Andrýs

et al. 2015

Mediators of Inflammation

Self Cite

View full text Add to dashboard Cite

Psoriasis is associated with metabolic activity of adipose tissue which produces pro- and anti-inflammatory adipokines. Goeckerman therapy (GT) represents an effective treatment of psoriasis. This study evaluated variation of selected inflammatory and metabolic markers during GT and the relationships between the markers, severity of the disease (PASI score), body mass, and the basic characteristics of the therapy. The study was conducted on a group of patients (n = 32) and on a control group (n = 24). Before GT, we found significantly elevated levels of proinflammatory CRP (p < 0.001) and leptin (p < 0.05) in psoriatic patients (compared to the controls). The therapy significantly decreased the levels of CRP and adiponectin. We found positive correlations between CRP and total duration of GT (p < 0.05) and CRP and the time of UV exposure (p < 0.01) and negative correlations between adiponectin and the total duration of GT (p < 0.05) and adiponectin and the application of CCT ointment (p < 0.001). From our results, we can conclude that GT causes partial reduction of both proinflammatory and anti-inflammatory markers. However, the levels of proinflammatory CRP and leptin remained significantly higher in the patients than in the control group.

show abstract

Section: Discussionmentioning

confidence: 99%

Selected Inflammatory and Metabolic Markers in Psoriatic Patients Treated with Goeckerman Therapy

Kondělková

Borská

Andrýs

et al. 2015

Mediators of Inflammation

Self Cite

View full text Add to dashboard Cite

show abstract

“…Remarkably, serum TLR2 was recently described to correlate with the presence of prosthetic joint infection in patients undergoing revision of joint arthroplasty, because of suspected local infection [23]; thus, circulating TLR2 may be considered a marker of the presence of bacterial components in the blood flow. Moreover, high levels of soluble TLR2 were shown in the sera of patients affected by psoriasis [21] and systemic lupus erythematosus [25], diseases in which innate immunity plays a major pathogenetic role [41, 42]. As such, high levels of soluble TLR2 may reflect the activation of innate inflammatory responses.…”

Section: Discussionmentioning

confidence: 99%

“…These molecules can be found in body fluids upon bacterial sensing [15–17] and, acting as decoy receptors for PAMPs, they negatively regulate membrane-bound TLR activation in order to prevent exaggerated innate immune activation [18–20]. Interestingly, soluble TLRs have been proposed as potential biomarkers for several inflammatory/infectious conditions, including IBD [21–26]. …”

Section: Introductionmentioning

confidence: 99%

Procoagulatory State in Inflammatory Bowel Diseases Is Promoted by Impaired Intestinal Barrier Function

Pastorelli

Dozio

Pisani

et al. 2015

Gastroenterology Research and Practice

View full text Add to dashboard Cite

Inflammatory and immune mediated disorders are risk factors for arterial and venous thromboembolism. Inflammatory bowel diseases (IBD) confer an even greater risk of thromboembolic events than other inflammatory conditions. It has been shown that IBD patients display defective intestinal barrier functions. Thus, pathogen-associated molecular patterns (PAMPs) coming from the intestinal bacterial burden might reach systemic circulation and activate innate immunity receptors on endothelial cells and platelets, promoting a procoagulative state. Aim of the study was to test this hypothesis, correlating the presence of circulating PAMPs with the activation of innate immune system and the activation of the coagulatory cascade in IBD patients. Specifically, we studied lipopolysaccharide (LPS), Toll-like receptor (TLR) 2, TLR4, and markers of activated coagulation (i.e., D-Dimer and prothrombin fragment F1+2) in the serum and plasma of IBD patients. We found that LPS levels are increased in IBD and correlate with TLR4 concentrations; although a mild correlation between LPS and CRP levels was detected, clinical disease activity does not appear to influence circulating LPS. Instead, serum LPS correlates with both D-Dimer and F1+2 measurements. Taken together, our data support the role of an impairment of intestinal barrier in triggering the activation of the coagulatory cascade in IBD.

show abstract

“…NF-κB is a major protein responsible for signaling production of tumor necrosis factor-α (TNF-α) and other pro-inflammatory interleukins [26]. Specifically, TLR2 and TLR4 have been shown to play a significant role in psoriasis and other cutaneous disease processes [26][27][28][29][30]. In a study investigating the expression of TLRs in cutaneous disease, TLR2 and TLR4 were shown to be disproportionally expressed in psoriasis affected epidermis [27].…”

Section: Vitamin Dmentioning

confidence: 99%

“…In a study investigating the expression of TLRs in cutaneous disease, TLR2 and TLR4 were shown to be disproportionally expressed in psoriasis affected epidermis [27]. The identification of augmented expression of TLRs in and their contribution to psoriasis is supported by numerous studies showing the role of various receptors in psoriasis including increased epidermal TLR2 expression [28][29]. Another study showed that TLR2 and TLR4 polymorphisms were found to increase patient susceptibility to psoriasis vulgaris [30].…”

Section: Vitamin Dmentioning

confidence: 99%

Psoriasis and Fat-soluble Vitamins: A Review

Usedom¹,

Neidig²,

Allen³

2017

J Clin Exp Dermatol Res

View full text Add to dashboard Cite

Fat-soluble vitamins exhibit numerous routes of immune modulation and specifically alter a variety of pathways in psoriasis pathology. Psoriasis, a chronic immune-mediated disease, often requires a combination of topical, oral, and occasionally, subcutaneous or intravenous therapies making disease management complex. With the complexity of treatment, patient adherence is reduced. Vitamin supplementation as an adjunctive treatment would minimize potential adverse effects from systemic medication, increase patient adherence and decrease overall cost. While vitamin A and D are effective topically, oral supplementation is not currently a mainstay of therapy although data exists to support such supplementation. Data on vitamin E and K implicate the significant role each has in the alteration of the inflammatory cascade responsible for psoriasis. Research showing fat-soluble vitamin deficiency in psoriasis exists and presents greater evidence for oral vitamin treatment in addition to first-line therapies. This review presents the mechanism of action in psoriasis of each fat-soluble vitamin and the data on the efficacy of oral fat-soluble vitamin supplementation in psoriasis and systemic inflammation. We also present fat-soluble vitamin deficiency data shown in psoriasis patients. With the evidence of their targeted mechanism of action, efficacy data with oral supplementation, and evidence of deficiency in patients, oral fat-soluble vitamins should be considered as an adjunct to therapy in psoriasis patients.

show abstract

Membrane and soluble Toll‐like receptor 2 in patients with psoriasis treated by Goeckerman therapy

Abstract: Membrane and soluble TLR2 may be involved in the pathogenesis of psoriasis. Both remained unchanged by GT.

Cited by 9 publications

References 37 publications

Selected Inflammatory and Metabolic Markers in Psoriatic Patients Treated with Goeckerman Therapy

Selected Inflammatory and Metabolic Markers in Psoriatic Patients Treated with Goeckerman Therapy

Procoagulatory State in Inflammatory Bowel Diseases Is Promoted by Impaired Intestinal Barrier Function

Psoriasis and Fat-soluble Vitamins: A Review

Contact Info

Product

Resources

About